IndoVac
IndoVac is a COVID-19 vaccine developed by Bio Farma, an Indonesian state-owned enterprise. The vaccine is based on a recombinant protein subunit platform, which uses a part of the virus to stimulate an immune response without causing the disease.
Development[edit | edit source]
The development of IndoVac began in response to the global COVID-19 pandemic. Bio Farma collaborated with various international and local institutions to expedite the research and development process. The vaccine underwent several phases of clinical trials to ensure its safety and efficacy.
Mechanism of Action[edit | edit source]
IndoVac works by introducing a harmless piece of the SARS-CoV-2 virus, specifically the spike protein, to the immune system. This protein is recognized by the immune system, which then produces antibodies. If the vaccinated individual is later exposed to the actual virus, their immune system can quickly recognize and combat the virus, preventing illness.
Clinical Trials[edit | edit source]
IndoVac underwent rigorous clinical trials, including Phase I, II, and III trials. These trials were conducted to assess the vaccine's safety, immunogenicity, and efficacy. The results from these trials indicated that IndoVac is effective in preventing COVID-19 and has a favorable safety profile.
Approval and Distribution[edit | edit source]
The vaccine received emergency use authorization from the Indonesian Food and Drug Authority (BPOM) and has been included in the national vaccination program. Bio Farma has ramped up production to meet both domestic and international demand.
Storage and Administration[edit | edit source]
IndoVac is stored at standard refrigeration temperatures, making it easier to distribute compared to some other COVID-19 vaccines that require ultra-cold storage. The vaccine is administered in two doses, given several weeks apart.
Impact[edit | edit source]
The introduction of IndoVac has significantly contributed to the vaccination efforts in Indonesia, helping to curb the spread of COVID-19 and reduce the severity of the disease in vaccinated individuals.
See Also[edit | edit source]
Related Pages[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
